Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3141999 | 0.85 | SCN9A (0.49) | SCN9APTPN1BRAF | |
| SCHEMBL3133764 | 0.83 | THRA (0.54) | SCN9APTPN1BRAF | |
| SCHEMBL6954319 | 0.75 | PTPN1 (0.53) | SCN9APTPN1BRAF | |
| SCHEMBL3131401 | 0.74 | BRAF (0.35) | BRAF | |
| SCHEMBL13884087 | 0.71 | BRAF (0.60) | BRAF | |
| SCHEMBL3133322 | 0.71 | HDAC1 (0.37) | SCN9A | |
| SCHEMBL3133343 | 0.70 | HSD17B14 (0.50) | SCN9APTPN1 | |
| SCHEMBL16966644 | 0.70 | SCN9A (1.00) | SCN9A | |
| SCHEMBL23761146 | 0.69 | NCF1 (0.54) | SCN9A | |
| SCHEMBL5074426 | 0.68 | CYP1A2 (0.44) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2010-01-07 | — | — | US | disclosed |
| EP-1899309-A1 | HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007003419-A1 | HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | TSHR, GHSR, TRHR | SCN9A 3770/4885PTPN1 924/4885BRAF 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.